Janssen’s Plivensia given thumbs down by US advisors

US regulatory advisors are not recommending approval of Johnson & Johnson’s Plivensia for rheumatoid arthritis, having concluded - based on the data available - that the benefits of the drug do not outweigh the potential risks.